Literature DB >> 24082555

Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer.

Sonia Batra1, Himanshu Nayak, Kalpna S Dave.   

Abstract

OBJECTIVES: To study the role of neoadjuvant chemotherapy (NACT) followed by surgical cytoreduction in the management of advanced epithelial ovarian cancers.
METHODS: A prospective hospital based study of patients with advanced epithelial ovarian cancers (stage III and IV) was conducted at Gujarat Cancer & Research Institute, Ahmedabad during August 2008 to August 2010. Total 50 patients were treated with NACT followed by surgical cytoreduction and followed up till August 2010. Response to NACT, optimal cytoreduction rate and overall response rate were analyzed.
RESULTS: There were 43 patients (86%) with stage III disease and 7 (14%) with stage IV disease. All patients were given NACT and after NACT, complete response occurred in 17 patients (34%), 27 (54%) had partial response. Optimal surgical cytoreduction could be achieved in 36(72%) of the patients. The median follow up was 19 months.
CONCLUSIONS: NACT followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers.

Entities:  

Keywords:  Advanced epithelial ovarian cancer; Neoadjuvant chemotherapy; Surgical cytoreduction

Year:  2012        PMID: 24082555      PMCID: PMC3526705          DOI: 10.1007/s13224-011-0106-8

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  14 in total

1.  Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.

Authors:  T Le; K Williams; M Senterman; L Hopkins; W Faught; M Fung-Kee-Fung
Journal:  Gynecol Oncol       Date:  2007-05-09       Impact factor: 5.482

2.  Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.

Authors:  Y Ansquer; E Leblanc; K Clough; P Morice; J Dauplat; P Mathevet; C Lhommé; C Scherer; J D Tigaud; M Benchaib; E Fourme; D Castaigne; D Querleu; D Dargent
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

3.  Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer.

Authors:  T Le; W Faught; L Hopkins; M Fung Kee Fung
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

4.  Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.

Authors:  W Kuhn; S Rutke; K Späthe; B Schmalfeldt; G Florack; B von Hundelshausen; D Pachyn; K Ulm; H Graeff
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

5.  Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000.

Authors:  Freddie Bray; Anja Helena Loos; Sandro Tognazzo; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2005-03-01       Impact factor: 7.396

6.  Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

Authors:  June Y Hou; Michael G Kelly; Herbert Yu; Jessica N McAlpine; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz
Journal:  Gynecol Oncol       Date:  2007-01-18       Impact factor: 5.482

7.  Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

Authors:  Filomena Mazzeo; Martine Berlière; Joseph Kerger; Jean Squifflet; Lionel Duck; Véronique D'Hondt; Yves Humblet; Jacques Donnez; Jean-Pascal Machiels
Journal:  Gynecol Oncol       Date:  2003-07       Impact factor: 5.482

8.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

9.  Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study.

Authors:  Y M Chan; T Y Ng; Hextan Y S Ngan; L C Wong
Journal:  Gynecol Oncol       Date:  2003-01       Impact factor: 5.482

Review 10.  Advanced ovarian cancer.

Authors:  M E van der Burg
Journal:  Curr Treat Options Oncol       Date:  2001-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.